Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers
May 10, 2022 | Kidney International Reports
Mohit Mathur, Jonathan Barratt, Yusuke Suzuki, Frank Engler, Marcela F. Pasetti, Jill Yarbrough, Susan Sloan, David Oldach